



CAPRION

Caprion Will Present Advantages And Challenges With FFPE Samples From Cancer Patients For Protein Biomarker Analysis By Mass Spectrometry at the 11th Annual WRIB (Workshop on Recent Issues in Bioanalysis) Conference in Los Angeles, April 4-7,2017.

Caprion Biosciences To Participate In A Round Table Discussion.

Montreal, QC, Canada – April 5th, 2017/CNW Telbec - **Caprion Biosciences Inc.** a North American (Canada) and European (Belgium), leading specialty laboratory CRO announced today that Dr. Lorella Di Donato, PhD, Senior Vice-President of Scientific Operations, will participate in a round table discussion on novel techniques to overcoming some of the main challenges with the analysis of FFPE tumor tissue from cancer patients, at the WRIB conference in Los Angeles.

Caprion Biosciences has demonstrated extensive capabilities for the identification of candidate protein biomarkers by analyzing FFPE tissue samples using a label-free mass spectrometry approach in a discovery setting. Furthermore, the approach can be used in a clinical setting for quantitative measurement of specific protein biomarkers using the AQUA (absolute quantification) approach which relies on heavy-labeled peptides (relative quantitation) as well as quantitative with high multiplexing capability.

Caprion Biosciences will be presenting its capabilities and expertise with FFPE tissue samples to perform biomarker analysis by mass spectrometry in a discovery setting, propose a review of key highlights from projects conducted in collaboration with the National Institute of Cancer (NCI) with a detailed presentation of quality control and sample processing methods.

Advantages And Challenges With FFPE Samples From Cancer Patients For Protein Biomarker Analysis By Mass Spectrometry

Topic 4B – Biomarkers Assays

Speaker: Lorella Di Donato, PhD, Senior Vice-President, Scientific Operations

Day 3, Thursday, April 6th, 2017, 4:00pm

About Caprion Biosciences, Inc.

Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Caprion's immune monitoring division, ImmuneCarta®, offers proprietary multiparametric flow cytometry services for functional analyses of innate and adaptive immune responses. Caprion's proteomics division, ProteoCarta™, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Based in Montreal, Canada, and Belgium, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 15 years. Caprion, a privately-held company, is majority owned by Global Healthcare Opportunities, or GHO Capital Partners LLP. For more information, please visit www.caprion.com.

Media Contact

Guyline Galipeau
Marketing Manager
Caprion Biosciences Inc.
ggalipeau@caprion.com
+1 514.360.3600

SOURCE Caprion Biosciences Inc.

RELATED LINKS:

<http://www.caprion.com>